Skip to content
Disclosery

PSquared Asset Management AG

Follow

13F filer, CIK 1623624, ZURICH, Switzerland

PSquared Asset Management AG reported $455,141,897 across 8 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000943663-25-000218

Period
2025-06-30
Reported value
$455M
Holdings
8
Top 10 weight
100%
New
4
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
TRIUMPH GROUP INC NEWnew+1,296,128$334M
SPRINGWORKS THERAPEUTICS INCnew+216,000$10.1M
E2OPEN PARENT HOLDINGS INCnew+3,125,000$10.1M
Kadded+82,078$6.53M
HOLXnew+100,000$6.52M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
INTRA-CELLULAR THERAPIES INCexited-229,086-$30.2M
DESPEGAR COM CORPexited-990,697-$18.6M
SLSRreduced-614,300-$2.82M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0000943663-25-000218, largest first. % of portfolio is the value over $455,141,897, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
TRIUMPH GROUP INC NEWTRIUMPH GROUP INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,296,128 shares 1,296,128$334M73.33%new
HESS CORPHESS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,208,996 shares; 2024Q4: 1,161,420 shares; 2025Q1: 250,744 shares; 2025Q2: 293,715 shares 293,715$40.7M8.94%+42,971
KKELLANOVAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 350,403 shares; 2025Q2: 432,481 shares 432,481$34.4M7.56%+82,078Timeline
SLSRSOLARIS RES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 4,547,184 shares; 2025Q2: 3,932,884 shares 3,932,884$18M3.96%-614,300Timeline
SPRINGWORKS THERAPEUTICS INCSPRINGWORKS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 216,000 shares 216,000$10.1M2.23%new
E2OPEN PARENT HOLDINGS INCE2OPEN PARENT HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 3,125,000 shares 3,125,000$10.1M2.22%new
HOLXHOLOGIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 100,000 shares 100,000$6.52M1.43%newTimeline
DCHDAUCH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 184,825 shares; 2025Q2: 369,395 shares 369,395$1.51M0.33%+184,570Timeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
INTRA-CELLULAR THERAPIES INCINTRA-CELLULAR THERAPIES INC229,086$30.2Mshares
DESPEGAR COM CORPDESPEGAR COM CORP990,697$18.6Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000943663-25-000218 base2025-08-13acceptance time not in the bulk data set